Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology - United Kingdom
doi 10.1111/all.14221
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Benralizumab for the Treatment of Severe Eosinophilic Asthma

Prescriber
Pharmacology
2018English

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Benralizumab Efficacy for Patients With Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2020English

Dupilumab Efficacy and Safety in Moderate-To-Severe Uncontrolled AsthmaEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Pediatrics
Child HealthPediatricsPerinatology
2018English

Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma

Prescriber
Pharmacology
2017English

Pharmacoeconomic Analysis of Therapy With Reslizumab in Severe Eosinophilic Asthma

Pulmonologiya
PulmonaryRespiratory Medicine
2018English

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Clinical Therapeutics
Pharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy